BIOCHEM BIOPH RES CO 润色咨询

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

出版年份:1959 年文章数:31561 投稿命中率: 开通期刊会员,数据随心看

出版周期:Weekly 自引率:4.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2023-12-11 ms1000000877479508 来自海南省

    11天了还是Submitted to journal,请问什么时候能进入下一节点啊

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2023-12-19 寻觅瓦尔登 来自上海

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:动物实验;心血管;基础
    经验分享:投的short communications,时间线参考:
    2023.12.03 Submitted to Journal
    2023.12.14 Pre-review changes required
    2023.12.15 Under Review
    2023.12.18 Accept
    一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。

    9

    展开9条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2024-02-21 ms8000000394868318 来自四川省

    偏重的研究方向:中药生发
    经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2024-02-23 1dd97911m23(暂无匿称) 来自北京

    偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎
    经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!

    5

    展开5条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    昨天 tou16689595638 来自广西

    好发,审稿快,可以聊聊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2024-03-13 weichusci01 来自广西

    还算好发,可以稳妥accept,着急想投稿的可以先聊聊

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2020-07-23 17142086d7m

    审稿速度:1.0 | 投稿命中率:100.0
    偏重的研究方向:神经生物学;细胞生物学;分子生物学
    经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!

    55

    展开55条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2020-05-05 12147f1dm17暂无昵称

    24小时内接受了,果然是神刊!

    26

    展开26条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2024-03-11 Tuo1887878 来自广西

    偏重的研究方向:分子生物学;肿瘤;细胞生物学
    经验分享:有办法可以快速accept,可以联系我

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:动物实验;心血管;基础<br>经验分享:投的short communications,时间线参考:<br>2023.12.03 Submitted to Journal<br>2023.12.14 Pre-review changes required<br>2023.12.15 Under Review<br>2023.12.18 Accept<br>一共给BBRC投过3次稿,拒稿转投1次,接收2次。这次从Under Review到接收只花了3天,个人感觉是BBRC更注重课题的创新,逻辑思路的清晰和语言的凝练。不需要有过多的数据,但是需要有新意。按照我的经验,越快审稿说明新意越足,中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向:中药生发<br>经验分享:2024.2.18晚上22.54投稿,2.19号凌晨12.59处于Submitted to Journal状态,到今天已经三天了还是Submitted to Journal状态,编号: BBRC-24-1364,期待能有个好结果吧,毕业用,不知道能不能来得及,唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向:鼻息肉;适应性免疫;人慢性鼻窦炎<br>经验分享:记录一下:投的short communication,编号:24-1285。2024.02.15 Submitted to journal,2024.02.21 Under Review。跪求诸神保佑文章可以accept!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2193798, encodeId=c6912193e98c7, content=好发,审稿快,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Mon Mar 18 09:28:54 CST 2024, time=昨天, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192962, encodeId=255d21929622c, content=还算好发,可以稳妥accept,着急想投稿的可以先聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/47914c6997134a928ed954f7a8071140-N1SdjCB9k2Cx.jpg, createdBy=0fcc9212232, createdName=weichusci01, createdTime=Wed Mar 13 14:31:22 CST 2024, time=2024-03-13, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0<br>偏重的研究方向:神经生物学;细胞生物学;分子生物学<br>经验分享:赶着毕业拿学位,投稿BBRC,非常给力!7月19日晚上提交,立刻分配了稿件号并with editor,7月21日下午稿件退回要求补充上传WB的original images,当天补充完提交,提交后1小时就under review,今天7月23日中午接收,从初次提交到接收用时4天,十分效率!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=55, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590238, encodeId=8fae5902380a, content=24小时内接受了,果然是神刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=252, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0f52242192, createdName=12147f1dm17暂无昵称, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192588, encodeId=06542192588e9, content=偏重的研究方向:分子生物学;肿瘤;细胞生物学<br>经验分享:有办法可以快速accept,可以联系我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:21:48 CST 2024, time=2024-03-11, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2192578, encodeId=6c8221925e871, content=偏重的研究方向:分子生物学;细胞生物学;癌症<br>经验分享:有办法快速accept,有需要可以找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/8162bc5d57234edb89dc546fca11f2b8-WHeBev04VHIs.jpg, createdBy=eb769208061, createdName=Tuo1887878, createdTime=Mon Mar 11 15:00:30 CST 2024, time=2024-03-11, status=1, ipAttribution=广西)]
    2024-03-11 Tuo1887878 来自广西

    偏重的研究方向:分子生物学;细胞生物学;癌症
    经验分享:有办法快速accept,有需要可以找我

    0

共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分